Erdafitinib Drug Asset Due Diligence Report 2026

This Erdafitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Erdafitinib can convert its Small molecule drug profile and FGFR1 x FGFR2 x FGFR3 x FGFR4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Erdafitinib (query alias: erdafitinib)
Modality / target	Small molecule drug; FGFR1 x FGFR2 x FGFR3 x FGFR4; FGFR1 antagonists, FGFR2 antagonists, FGFR3 antagonists
Highest global status	Approved
Originator	Astex Pharmaceuticals, Inc.
Active developers	Janssen Research & Development LLC, Janssen-Cilag International NV, Pivotal SL

The MCP disease footprint includes Locally Advanced Urothelial Carcinoma, Metastatic urothelial carcinoma, Unresectable Urothelial Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06919965	Phase 3	Recruiting	220	Disease-free Survival (DFS)
NCT06511648	Phase 2	Recruiting	90	Pathological complete response (pCR)
NCT06351371	Phase 2	Active, not recruiting	35	Objective Response Rate (ORR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Chemoablation with oral erdafitinib in recurrent FGFR3-altered non–muscle-invasive bladder cancer: A phase II window-of-opportunity trial.

Phase 2; n=20; evaluation: Positive. Reported fields: CR = 55.0 %

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and <i>FGFR</i> Alterations: Final Results From the Phase II NORSE Study

Phase 2; n=87; evaluation: Positive. Reported fields: TRAE(Grade ≥3) = 45.5 % ; TRAE(Grade ≥3) = 46.5 %

Use of FGFR inhibitors for treatment of primary CNS tumors

Not Applicable; n=9; evaluation: Positive. Reported fields: AE = Toxicities included fatigue, visual changes, hyperphosphatemia and stomatitis. Two patients required dose reductions and four required discontinuation due to toxicity (visual changes - 1, hyperphosphatemia - 1 and fatigue - 2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Erdafitinib addresses Locally Advanced Urothelial Carcinoma, Metastatic urothelial carcinoma, Unresectable Urothelial Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-04-05	Immunomedics partners with Janssen to market erdafitinib for metastatic urothelial cancer in the US.	NDA/BLA	US$15.0M stated total
2008-06-09	Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V.	Preclinical	US$37.4M upfront; US$500.0M stated total
2006-03-13	Astex announces new drug discovery collaboration with University of Newcastle upon Tyne and Cancer Research Technology Limited	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Erdafitinib formulations and osmotic systems for intravesical administration”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO